Mouse Anti-Human CD105
Product number PDZMM110
Host species Mouse
Target species Human
Suitable for: IHC-P, WB, ELISA, Immunomicroscopy, Dot blot, ICC, IHC-Fr
Immunogen A KLH-conjugated synthetic peptide derived from human CD105 protein was used for immunization.
Storage instructions Shipped at 4 °C. Store at -20 °C. Avoid freeze/thaw cycle. Please see notes section.
Storage buffer Phosphate buffered saline pH 7.4, contains stabilizer and ≤0.09% sodium azide.
Purity immunogen affinity or SpG purified
Purification notes This product was prepared by immunoaffinity chromatography using immunogen peptide coupled to Sepharose 4B.
Conjugation notes –
General notes For extended storage aliquot contents and freeze at -20 °C or below. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4 °C as an undiluted liquid. Dilute only prior to immediate use.
Our customer’s feedback says the antibody worked great. If in case the antibody fails to give results then please contact our scientific support team for assistance.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end-user.
Product Usage Information:
Western Blotting 3-5 ug/ml
Immunohistochemistry (Paraffin) 5-10 ug/ml
Immunohistochemistry (Frozen) 5-10 ug/ml
Immunofluorescence 5-10 ug/ml
Flow Cytometry 5-10 ug/ml
Please note: All products are “FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES”
CD105 (Endoglin) is a type I transmembrane protein reported to induce activation and proliferation of endothelial cells. In addition, CD105 is expressed in haematological malignancies and the vessels of solid tumours.
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. After receiving aliquot the antibody and store at –20°C.
Terms and conditions
Guarantee only valid for products bought direct from PADZA or one of our authorized distributors
Note: This product has originally been developed at Avicenna Research Institute, Tehran, IRAN and assigned to PADZA Company according to contract 98/15/191dated 98/01/